EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

NCT05150236 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Prostate Cancer
Neoplasms by Site
Neoplasms
Prostatic Disease

Interventions

DRUG: 177Lu-PSMA-617
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]